Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia.

< BACK TO ARCHIVE


Papers: 11 Jul 2020 - 17 Jul 2020


Human Studies, Pharmacology/Drug Development


2020


J Pain Res


http://www.ncbi.nlm.nih.gov/pubmed/32669869?dopt=Abstract


13

Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia.

Authors

Design of Phase 3 Studies Evaluating Vixotrigine for Treatment of Trigeminal Neuralgia.
Kotecha M, Cheshire WP, Finnigan H, Giblin K, Naik H, Palmer J, Tate S, Zakrzewska JM
J Pain Res. 2020; 13:1601-1609.
PMID: 32669869.

Abstract

Vixotrigine (BIIB074) is a voltage- and use-dependent sodium channel blocker. These studies will evaluate the efficacy and safety of vixotrigine in treating pain experienced by patients with trigeminal neuralgia (TN) using enriched enrollment randomized withdrawal trial designs.
Read This Paper